Hepatobiliary and intestinal elimination of darunavir in an integrated preclinical rat model

References

• Annaert P, Ye ZW, Stieger B, Augustijns P. (2010). Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiot Fate Foreign Compd Biol Syst 40:163–76
   PubMed Web of Science ®Google Scholar
• Annaert PP, Turncliff RZ, Booth CL, et al. (2001). P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab Dispos 29:1277–83
   PubMed Web of Science ®Google Scholar
• Balani SK, Zhu T, Yang TJ, et al. (2002). Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos Biol Fate Chem 30:1059–62
   PubMed Web of Science ®Google Scholar
• Brouwers J, Mols R, Annaert P, Augustijns P. (2010). Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling. Biopharm Drug Dispos 31:278–85
   PubMed Web of Science ®Google Scholar
• Dantzig AH, Shepard RL, Law KL, et al. (1999). Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290:854–62
   PubMed Web of Science ®Google Scholar
• Dautrey S, Felice K, Petiet A, et al. (1999). Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates. Br J Pharmacol 127:1728–34
   PubMed Web of Science ®Google Scholar
• De Bruyn T, Chatterjee S, Fattah S, et al. (2013). Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 9:589–616
   PubMed Web of Science ®Google Scholar
• De Bruyn T, Fattah S, Stieger B, et al. (2011). Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3. J Pharm Sci 100:5018–30
   PubMed Web of Science ®Google Scholar
• Gramatté T, Oertel R. (1999). Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 66:239–45
   PubMed Web of Science ®Google Scholar
• Haslam IS, Wright JA, O’Reilly DA, et al. (2011). Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2). Drug Metab Dispos Biol Fate Chem 39:2321–8
   PubMed Web of Science ®Google Scholar
• Holmstock N, Mols R, Annaert P, Augustijns P. (2010). In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption. Drug Metab Dispos Biol Fate Chem 38:1407–10
   PubMed Web of Science ®Google Scholar
• Lachau-Durand S, Annaert P, Steemans K, et al. (2006). Transport characteristics of the HIV protease inhibitor darunavir (TMC114) in Caco-2 monolayers. Available from: https://lirias.kuleuven.be/handle/123456789/58573 [last accessed 27 Aug 2013]
   Google Scholar
• MacLean C, Moenning U, Reichel A, Fricker G. (2008). Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos Biol Fate Chem 36:1249–54
   PubMed Web of Science ®Google Scholar
• Mallants R, Van Oosterwyck K, Van Vaeck L, et al. (2005). Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 35:1055–66
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Baktir G, Radschuweit A, et al. (1998). P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16–24
   PubMed Web of Science ®Google Scholar
• Stappaerts J, Annaert P, Augustijns P. (2013). Site dependent intestinal absorption of darunavir and its interaction with ketoconazole. Eur J Pharm Sci Off J Eur Fed Pharm Sci 49:51–6
   PubMed Web of Science ®Google Scholar
• Strelevitz TJ, Foti RS, Fisher MB. (2006). In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334–41
   PubMed Web of Science ®Google Scholar
• Sugano K, Kansy M, Artursson P, et al. (2010). Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 9:597–614
   PubMed Web of Science ®Google Scholar
• Takara K, Ohnishi N, Horibe S, Yokoyama T. (2003). Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. Drug Metab Dispos Biol Fate Chem 31:1235–9
   PubMed Web of Science ®Google Scholar
• Vermeir M, Lachau-Durand S, Mannens G, et al. (2009). Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos Biol Fate Chem 37:809–20
   PubMed Web of Science ®Google Scholar
• Wetterich U, Spahn-Langguth H, Mutschler E, et al. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514–22
   PubMed Web of Science ®Google Scholar
• Ye Z-W, Camus S, Augustijns P, Annaert P. (2010). Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos 31:178–88
   PubMed Web of Science ®Google Scholar